Podcast

Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer

Author(s):

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we had the pleasure of speaking with Everett Vokes, MD, John E. Ultmann Professor, physician-in-chief, and chair of the Department of Medicine at the University of Chicago Medicine. Dr. Vokes is an internationally renowned expert in head and neck cancer, having pioneered combination chemotherapy and radiation as a first-line treatment for patients.

Dr. Vokes is also the recipient of the new Translational Research Professorship from the American Society of Clinical Oncology, as well as the Francis L. Lederer Foundation grant for research on the malignancies of the upper aerodigestive tract.

In 2013, Dr. Vokes was recognized as the OncLive® Giant of Cancer Care for Head and Neck Cancer for his tremendous achievements.

In our exclusive interview, Dr. Vokes discussed the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Related Videos
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Ben Levy, MD, and Yan Leyfman, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"